Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22023888 | 0.85 | CRBN (0.32) | LMNACRBN | |
| SCHEMBL22024311 | 0.79 | CRBN (0.31) | LMNACRBN | |
| SCHEMBL21565355 | 0.79 | LMNA (0.33) | LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL21191593 | 0.79 | CCR2 (0.36) | ALDH1A1CRBN | |
| SCHEMBL7946755 | 0.79 | ALDH1A1 (0.34) | LMNAALDH1A1SMN1; SMN2CRBN | |
| SCHEMBL14916972 | 0.79 | ALDH1A1 (0.34) | LMNAALDH1A1SMN1; SMN2CRBN | |
| SCHEMBL11917928 | 0.79 | ALDH1A1 (0.34) | LMNAALDH1A1SMN1; SMN2CRBN | |
| SCHEMBL20262367 | 0.78 | ALDH1A1 (0.30) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL22024310 | 0.78 | CRBN (0.33) | LMNAALDH1A1SMN1; SMN2CRBN | |
| SCHEMBL20804241 | 0.78 | LMNA (0.33) | LMNACRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210345611-A1 | EXTENDED AND CONTINUOUS RELEASE COMPOSITIONS FOR PLANT HEALTH AND METHOD OF USE | VERDESIAN LIFE SCIENCES U.S., LLC | 2021-11-11 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
| WO-2020046932-A1 | EXTENDED AND CONTINUOUS RELEASE COMPOSITIONS FOR PLANT HEALTH AND METHODS OF USE | VERDESIAN LIFE SCIENCES U.S., LLC (US) | 2020-03-05 | — | — | WO | disclosed |
| US-7273885-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210345611-A1 | EXTENDED AND CONTINUOUS RELEASE COMPOSITIONS FOR PLANT HEALTH AND METHOD OF USE | APEH, GET3, NSF | LMNA 2333/4885SLC2A1 74/4885ALDH1A1 2889/4885 |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | LMNA 2656/4885SLC2A1 3821/4885ALDH1A1 2352/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | LMNA 2656/4885SLC2A1 3821/4885ALDH1A1 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.